Lilly Asia Ventures contributed to a round that will fund clinical trials for Carsgen's immuno-oncology drug pipeline and the enhancement of its manufacturing capabilities.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The Heska-backed company is currently working on a covid-19 test, its latest round having pushed its total equity funding to about $30m.

University of Colorado and Osage University Partners both backed a round that took the immune regulation-focused university spinout's total funding to at least $106m.

Pfizer was among the participants as the Asia-focused cancer and cardiorenal drug developer raised $310m in crossover financing.

Lilly Asia Ventures returned for a round that will fund clinical development of Gracell Biotechnologies' immuno-oncology drug pipeline.

Novo, Bristol Myers-Squibb and Merck Group scored exits as the fibrosis and cancer drug developer priced its shares in the middle of the IPO's range.

Sanofi Ventures and Children's Hospital Colorado have returned to back Q32 Bio, an immune regulation-focused university spinout that has now raised at least $106m to date.

ORI Healthcare Fund II has a target of $400m and pharmaceutical firm Hepalink could potentially provide up to $80m for the vehicle.

4100 Group led an extension to the Stanford-StartX Fund-backed healthcare AI technology provider's latest round, which now stands at $30m.